Chemotherapy before stem cell transplant for NK/T-cell lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three chemotherapy drugs given before a stem cell transplant to treat NK/T-cell lymphoma. The goal is to see if this conditioning regimen helps the transplant succeed and reduces side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have NK/T-cell lymphoma that has responded to treatment or you have relapsed/refractory disease.
- You have a suitable stem cell donor (related or unrelated) with enough HLA matching.
- Your overall health is good, with no major organ problems (heart, lungs, liver, kidneys).
- You are not pregnant or breastfeeding, and you agree to use contraception if needed.
- You do not have active infections like HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, selinexor and azacitidine, given after a stem cell transplant to help prevent the lymphoma from coming back. The goal is to see if this combination is safe and effective as a maintenance treatment.
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
This study tests a combination of four chemotherapy drugs given before a stem cell transplant to help prepare the body and reduce the chance of lymphoma returning. It is for people with certain types of lymphoma who are scheduled for this transplant.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
This trial tests a stronger chemo and radiation plan before a stem cell transplant for people with myelodysplastic syndrome (a blood disorder) or acute myeloid leukemia (a blood cancer). The goal is to help the transplant work better and reduce the chance of the disease coming back.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.